Phase II Study of Rituximab Plus MG4101 in Patients With Relapsed or Refractory Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs MG 4101 (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 31 Oct 2019 Planned End Date changed from 1 Jul 2021 to 31 Dec 2022.
- 31 Oct 2019 Planned primary completion date changed from 1 May 2019 to 1 May 2020.
- 31 Oct 2019 Status changed from not yet recruiting to recruiting.